Version No: MSDS/Bort-AUS/DP-001 Effective Date: 26th April 2021

Bortezomib Powder for Injection 1 mg/vial and 3.5 mg/vial

SECTION 1 – PRODUCT AND COMPANY IDENTIFICATION

Product Name: Bortezomib Powder for Injection 1 mg/vial and 3.5 mg/vial

Details of the Supplier of the Safety Data Sheet		
Manufacturer:	Sponsor:	
Intas Pharmaceuticals Ltd.	Accord Healthcare Pty Ltd	
Plot No. 5, 6 and 7, Pharmez,	Level 24, 570 Bourke Street,	
Near village Matoda,	Melbourne, VIC, 3000,	
Sarkhej-Bavla National Highway No. 8-A,	Australia	
Sanand Taluka, Ahmedabad, Gujarat, IN-		
382213 India		

SECTION 2 – COMPOSITION, INFORMATION ON INGREDIENTS

Components	CAS Number	Weight %	Synonyms	EINECS-	Classificatio
				No.	n
Mannitol	69-65-8	91	-	200-711-8	-
Bortezomib	179324-69-7	9	-	-	T+;
					R26/27/28
					Xi; R36/38
					T; R48/23/24

SECTION 3 - HAZARDS IDENTIFICATION

General hazard information: Cytotoxic drug.

Very toxic if inhaled, in contact with skin and if

swallowed.

This product contains ingredients which may have

reproductive effects.

Toxic: danger of serious damage to health by prolonged exposure through inhalation, in contact with skin and if

swallowed.

Irritating to eyes, respiratory system and skin.

Indication of danger : T+ - Very toxic.

Version No: MSDS/Bort-AUS/DP-001 Effective Date: 26th April 2021



Most important hazards Risk Phrases

: R26/27/28 - Very toxic by inhalation, in contact with

skin and if swallowed.

R36/38 - Irritating to eyes and skin.

R48/23/24 - Toxic: danger of serious damage to health by prolonged exposure through inhalation and in contact

with skin.

Carcinogenicity rating:

EC: : None.

SECTION 4 - FIRST AID MEASURES

Eye contact : In the case of contact with eyes, rinse

immediately with plenty of water for 15 minutes

and seek medical attention.

Skin contact : After contact with skin, wash immediately with

plenty of water. Immediately remove contaminated clothing and shoes and place in sealable, properly labeled waste disposal bag. Over bag into a sealable, properly labeled waste disposal bag. Material must be disposed of as hazardous drug waste. Seek medical attention if

symptoms appear.

Ingestion: If ingested, seek medical attention immediately

and show the label.

Inhalation : Move to fresh air immediately. If experiencing

difficulty breathing, seek medical attention.

Notes to physician: : Treat symptomatically. Please refer to

Monograph for Bortezomib Powder for Injection on medical monitoring guidelines for personnel

working with cytotoxic compounds.

Protection for first: Please wear eye and skin protection.

Version No: MSDS/Bort-AUS/DP-001 Effective Date: 26th April 2021

aiders

SECTION 5 - FIRE FIGHTING MEASURES

Suitable extinguishing

media

: Water fog or mist.

carbon dioxide (CO₂).

dry powder. dry sand. foam.

Extinguishing media which must not be used for safety

reasons

None.

Specific hazards: : None

Special protective

equipment for firefighters

Wear a self-contained breathing apparatus and

full protective gear.

Combustion products or

resulting gases

Carbon dioxide (CO₂)

Carbon monoxide Nitrogen oxides (NOx)

water

SECTION 6 - ACCIDENTAL RELEASE MEASURES

Personal precautions

For milligram quantities: Disposable dust impervious protective suit and shoe covers. Full face negative pressure respirator with HEPA (ABEK-P3 in EU) cartridges. Two pairs of FDA approved "chemo" gloves. The outer glove shall

be taped to the jumpsuit.

For gram quantities: Clean-up personnel must wear self-contained breathing apparatus (SCBA) and totally encapsulated chemical resistant suit. Two pairs of FDA approved "chemo" gloves. The outer glove shall be taped to the jumpsuit. 2 pairs of gloves chemically-resistant to the decontamination solution/solvent. The outer glove shall be taped to the jumpsuit.

glove shall be taped to the jumpsuit.

Environmental Protection: Do not allow significant quantities of product to

enter drains, sewers or public waterways.

Methods for cleaning up: : Evacuate area.

Version No: MSDS/Bort-AUS/DP-001 Effective Date: 26th April 2021

> Next, use disposable towels moistened with an appropriate cleaning agent (i.e. solvent. detergent and water, etc.) to complete cleaning process. A designated HEPA vacuum can be used as an alternative cleaning method for large spills of powder. All waste must be placed in a sealable, properly labeled waste disposal bag. Over bag into a sealable, properly labeled waste disposal bag. Material must be disposed of as hazardous drug waste.

SECTION 7 - HANDLING AND STORAGE

Handling:

Technical measures

/precautions

Safe handling advice

Handle and store per labelled instructions.

Work only in a designated area. Handle on easily cleanable, nonporous, smooth surfaces. Refer to

Section 8 for exposure controls and personal

protection.

Storage:

Technical measures/storage:

conditions

Store in tightly sealed containers. Protect from moisture. Primary containers shall be overpacked into Nalgene or other sealed unbreakable containers. Appropriate warning labels shall be affixed to both containers. Compounds shall be transported only when overpacked as described above and on carts or transport devices that minimize the risk of spills. Primary containers shall be tightly sealed immediately after use. Sealed primary containers shall be handled only with gloves. Contamination of the exterior of the

primary container should be exposed.

No special restrictions on storage with other **Incompatible products**

products.

Specific use(s): None under normal use.

Version No: MSDS/Bort-AUS/DP-001 Effective Date: 26th April 2021

SECTION 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION

Exposure limits

Components	OEL (TWA – 8 hr)	OEL (STEL)	OEL (Ceiling)	PBOEL	ASL
Bortezomib (10%)	530 ng/m³	-	-	Category 4 Repro	0.2 μg/m ²
179324-69-7					

Exposure controls / personal protection

Engineering controls

Vented balance safety enclosures required for weighing/transferring or manipulating less than 200 milligram amount of dry solids. Glove box isolater required for greater than 200 milligram quantity manipulating of dry solids. All contaminant devices shall be exhausted directly following HEPA filtration.

Activities that can result in the generation or release of liquid aerosols, splatters or sprays require the use of the following containment devices:

- Directional laminar flow cabinets (vertical) equipped with HEPA filters.
- Type II B 2 biological safety cabinets.
- Glove box isolators.

Containment devices must be exhausted directly through a dedicated stack. Exhausted air many not be recirculated back to the room.

Directional laminar flow cabinets (vertical) shall also be used to control powder aerosols that may be released from vacuum ovens.

Respiratory protection

Engineering Controls are required for handling Category 4 compounds.

Respirators providing HEPA filtration (ABEK-P3 in EU) are requied for dosing animals and for all related animal care activites, such as cage washing, handling excetera and bedding changes. Repirators shall also be used in the event of spills and for non-routine work activites, such as changing HEPA filters or cleaning biological safety cabinets. Please consult your local industrial hygienist to obtain the required respiratory protection and training if respirators are to be worn.

Version No: MSDS/Bort-AUS/DP-001 Effective Date: 26th April 2021

Hand protection : Wear 2 pairs of nitrile gloves when handling as a

solid or liquid formulation. When handling solutions, wear chemical-resistant gloves appropriate for the

solvent(s) making up the solution.

Eye protection : Wear eye and face protection.

Safety glasses with side-shields recommended.

Goggles recommended if potential exists for direct

exposure to dust or splashes

Skin and body protection : Wear disposable dust impervious protective suit and

shoe covers.

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES

General Information

Physical state : Powder

Colour : White to off-white

Important Health Safety and Environmental Information

Flash point:Not applicablepH:Not applicableWater solubility: \pm 80 mg/mL

Other information

Melting point/range: : 165 °C

Explosive properties: : Not applicable

SECTION 10 - STABILITY AND REACTIVITY

Chemical stability: : Stable under recommended storage conditions.

Materials to avoid : Strong oxidants.

Conditions to avoid : Heat, flames and sparks.

Avoid moisture.

Hazardous Polymerization: Hazardous polymerisation does not occur.

Version No: MSDS/Bort-AUS/DP-001 Effective Date: 26th April 2021

SECTION 11 - TOXICOLOGY INFORMATION

Acute toxicity

Eye contactMethodMay cause severe eye irritation.Based on component data.

(Bortezomib)

Skin contact : Causes skin irritation.

Very toxic in contact with skin.

Method : Based on component data.

(Bortezomib)

Ingestion : Very toxic if swallowed.

Oral dose at 0.7 mg/kg in female monkeys was fatal, but not in male monkey tested at this dose. IV data indicates significant potential to be toxic or lethal at

doses < 2 mg/kg in rats and mice.

Inhalation : May be very toxic if inhaled.

Sub-Chronic / Chronic Toxicity

Application Route	Species	Dosing	Result
Intravenous (IV)	-	-	effects consistent with
administration			cytotoxic drugs (i.e.
			gastrointestinal (GI)
			Tract, blood, liver)

Specific effects

Target Organ(s) : gastrointestinal tract, liver, reproductive system,

eyes, skin, blood, kidney

Reproductive effects : Resulted in impaired fertility in animal studies.

Developmental effects : Developmental studies in rats and rabbits resulted in

embryo/fetal death only at maternally toxic dosages,

but no direct toxicity to the embryo/fetus.

Carcinogenic effects : Not Available

Genotoxic effects : Not mutagenic.

Not clastogenic.

Method : microbial (Ames) mutagenicity assay

in vivo rodent micronucleus bone marrow assay

in vitro chromosomal aberrations assay

(chinese hamster ovary cells)

Effective Date: 26th April 2021 Version No: MSDS/Bort-AUS/DP-001

SECTION 12 - ENVIRONMENTAL IMPACT INFORMATION

Ecotoxicity

Ecotoxicity effects This product has no known eco-toxicological effects.

Aquatic toxicity effects This product has no known aquatic toxicological

effects.

Persistence / degradability

Unknown on product. Bioaccumulation Unknown on product. : **Aquatic Toxicity** Unknown on product.

SECTION 13 - DISPOSAL INFORMATION

Waste from residues / unused products

Waste disposal must be in accordance with appropriate US, Federal, State and International regulations. This product, if unaltered by use, may be disposed of by treatment at a permitted facility or as advised by your local hazardous waste regulatory

authority.

Contaminated packaging Empty packing materials should be handled

according to local current procedures or according to

local by-laws or national laws.

SECTION 14 - TRANSPORTATION INFORMATION

IATA/ICAO

ID/UN No. UN 3249

Proper shipping name UN 3249, Medicine, toxic, solid n.o.s. (containing

bortezomib), 6.1, II

Hazard class 6.1 : Packing group PG II : IATA - label Toxic (6.1)

IMO/IMDG

UN/Id No. UN3249 :

Proper shipping name : UN 3249, Medicine, toxic, solid n.o.s. (containing

bortezomib), 6.1, II

Hazard class 6.1 : Packing group PG II : **IMDG-labels** Toxic (6.1)

Version No: MSDS/Bort-AUS/DP-001 Effective Date: 26th April 2021

ADR/RID

ADR/RID UN/Id No. : UN 3249

Proper shipping name : UN 3249, Medicine, toxic, solid n.o.s. (containing

bortezomib), 6.1, II

Hazard class/item No. letter
ADR/RID-labels
: 6.1, PG II
Toxic (6.1)
: 61GT2-II

SECTION 15 - REGULATORY INFORMATION

Indication of danger : T+ - Very toxic.

Contains : Bortezomib



R -phrase(s)

R26/27/28	Very toxic by inhalation, in contact with skin and if swallowed.	
R36/38	Irritating to eyes and skin.	
R48/23/24	Toxic: danger of serious damage to health by prolonged exposure through inhalation	
	and in contact with skin.	

S -phrase(s)

S26	In case of contact with eyes, rinse immediately with plenty of water and seek medical
	advice.
S28	After contact with skin, wash immediately with plenty of water and soap.
S38	In case of insufficient ventilation, wear suitable respiratory equipment.
S45	In case of accident or if you feel unwell, seek medical advice immediately (show the
	label where possible)
S53	Avoid exposure - obtain special instructions before use.
S36/37/39	Wear suitable protective clothing, gloves and eye/face protection.

Version No: MSDS/Bort-AUS/DP-001 Effective Date: 26th April 2021

SECTION 16 - OTHER DATA

Additional advice:

: Consult your supplier if the material is to be used for special applications such as in the food industry or for hygiene, medical or surgical end-use.

Text of R phrases mentioned in Section 2 and 3

R26/27/28	Very toxic by inhalation, in contact with skin and if swallowed.
R36/38	Irritating to eyes and skin.
R48/23/24	Toxic: danger of serious damage to health by prolonged exposure through inhalation
	and in contact with skin.

Data Sources: Publicly available toxicity information. Safety data sheets for individual ingredients.

The information in this document is believed to be correct as of the date issued. HOWEVER, NO WARRANTY OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR ANY OTHER WARRANTY IS EXPRESSED OR IS TO BE IMPLIED REGARDING THE ACCURACY OR COMPLETENESS OF THIS INFORMATION, THE RESULTS TO BE OBTAINED FROM THE USE OF THIS INFORMATION OR THE PRODUCT, THE SAFETY OF THIS PRODUCT, OR THE HAZARDS RELATED TO ITS USE. This information and product are furnished on the condition that the person receiving them shall make his own determination as to the suitability of the product for his particular purpose and on the condition that he assume the risk of his use thereof.